GHO

CobbleStone Software Included in Top 10 AI Healthcare Solution Providers in 2023 by GHO

Retrieved on: 
Tuesday, January 16, 2024
CLM, Software, EVP, SPARK, Machine learning, Metadata, Cobblestone, AI, HIPAA, GHO, Health, Medical device

PRINCETON, N.J., Jan. 16, 2024 /PRNewswire-PRWeb/ -- CobbleStone Software – a recognized Leader in contract lifecycle management (CLM) according to the SPARK Matrix™ 2023 Report– was recently interviewed by GHO following the announcement of the Top 10 AI Healthcare Solution Providers list.

Key Points: 
  • PRINCETON, N.J., Jan. 16, 2024 /PRNewswire-PRWeb/ -- CobbleStone Software – a recognized Leader in contract lifecycle management (CLM) according to the SPARK Matrix™ 2023 Report – was recently interviewed by GHO following the announcement of the Top 10 AI Healthcare Solution Providers list.
  • "We are thrilled to be included among the Top 10 AI Healthcare Solution Providers.
  • Our dedication to all industries, including healthcare, is unmatched with the aid of our insightful AI tool that has many features beneficial to healthcare professionals."
  • "We are thrilled to be included among the Top 10 AI Healthcare Solution Providers.

Stuart Quin joins GHO Capital as Partner

Retrieved on: 
Thursday, January 4, 2024
GHO, Partner, Sale, Acquisition, Cinven, Medica, Doctor of Philosophy, Teleradiology, MEDICA Group, Diagnosis, IK Partners, Patient, Pharma, NHS, Capital, London Stock Exchange, Pharmaceutical industry

London, UK – 4 January 2024: Global Healthcare Opportunities, or GHO Capital Partners LLP (“GHO”), the European specialist investor in global healthcare, is pleased to announce today that Stuart Quin joins as a Partner.

Key Points: 
  • London, UK – 4 January 2024: Global Healthcare Opportunities, or GHO Capital Partners LLP (“GHO”), the European specialist investor in global healthcare, is pleased to announce today that Stuart Quin joins as a Partner.
  • Stuart, who holds a PhD in Immunology, has nearly two decades of experience within private equity, principally at 3i, and in healthcare leadership across Diagnostics, Pharma and Biotech.
  • The Partners at GHO Capital commented: “One of our core principles at GHO in the pursuit of better, faster and more accessible healthcare is that we don’t just invest in companies, we focus on strategic alignment and collaboration with management teams.
  • We are very excited to welcome Stuart to our leadership team to strengthen our ability to build the next generation of healthcare together.”
    Stuart Quin, Partner at GHO Capital, said: “GHO Capital is Europe’s leading healthcare specialist private equity firm, dedicated to making a difference for patients, healthcare systems, and society, whilst delivering long-term sustainable value to stakeholders.

Stuart Quin joins GHO Capital as Partner

Retrieved on: 
Thursday, January 4, 2024
GHO, Partner, Sale, Acquisition, Cinven, Medica, Doctor of Philosophy, Teleradiology, MEDICA Group, Diagnosis, IK Partners, Patient, Pharma, NHS, Capital, London Stock Exchange, Pharmaceutical industry

London, UK – 4 January 2024: Global Healthcare Opportunities, or GHO Capital Partners LLP (“GHO”), the European specialist investor in global healthcare, is pleased to announce today that Stuart Quin joins as a Partner.

Key Points: 
  • London, UK – 4 January 2024: Global Healthcare Opportunities, or GHO Capital Partners LLP (“GHO”), the European specialist investor in global healthcare, is pleased to announce today that Stuart Quin joins as a Partner.
  • Stuart, who holds a PhD in Immunology, has nearly two decades of experience within private equity, principally at 3i, and in healthcare leadership across Diagnostics, Pharma and Biotech.
  • The Partners at GHO Capital commented: “One of our core principles at GHO in the pursuit of better, faster and more accessible healthcare is that we don’t just invest in companies, we focus on strategic alignment and collaboration with management teams.
  • We are very excited to welcome Stuart to our leadership team to strengthen our ability to build the next generation of healthcare together.”
    Stuart Quin, Partner at GHO Capital, said: “GHO Capital is Europe’s leading healthcare specialist private equity firm, dedicated to making a difference for patients, healthcare systems, and society, whilst delivering long-term sustainable value to stakeholders.

Joseph Jimenez, Global Quality Leader, Joins Validant Group

Retrieved on: 
Thursday, October 5, 2023
Professional Services, Health, FDA, Medical Devices, Consulting, Pharmaceutical, Biotechnology, Multimedia, Teva Active Pharmaceutical Ingredients, GHO, Quality control, Partner, Procter & Gamble, Teva Pharmaceuticals, Mentorship, Pharmaceutical industry, Medical device, Management, Teva, Validation (drug manufacture)

The Validant Group, a leading global provider of comprehensive and innovative regulatory consulting services for the life sciences industry, today announced that Joseph Jimenez has joined the firm as Partner.

Key Points: 
  • The Validant Group, a leading global provider of comprehensive and innovative regulatory consulting services for the life sciences industry, today announced that Joseph Jimenez has joined the firm as Partner.
  • Joseph is a global quality leader with a career spanning nearly 30-years in the pharmaceutical, medical device, human tissue, and consumer goods organizations.
  • His experience enhances the Validant Group’s quality assurance and strategic regulatory compliance capabilities.
  • The Validant Group is a global, full-service life science consulting company focused on managing and resolving complex regulatory issues.

Green Brick Partners, Inc. Announces New Land Acquisition in Vero Beach, FL

Retrieved on: 
Wednesday, October 4, 2023
The Country Club, GHO, Treasure Coast, Golf, Green, Country club, NYSE, Hotel, Grand Harbour

Vero Beach is about 80 miles north of Palm Beach, FL and is an important city in the Treasure Coast area.

Key Points: 
  • Vero Beach is about 80 miles north of Palm Beach, FL and is an important city in the Treasure Coast area.
  • The city features peaceful beaches and is one of the most desirable areas to live in Florida.
  • GHO Homes will be offering higher-end homes with waterfront and golf course views priced from $1.5 to $2.5 million.
  • Construction of the homes is currently slated to start at the end of 2023, and the Company anticipates opening for sales in October 2023.

GHO Capital and Partners Group invest in Sterling Pharma Solutions, a leading pharmaceutical development and manufacturing organization

Retrieved on: 
Saturday, May 27, 2023
LLP, Partnership, CG, GHO, ERM, Partner, API, AlpInvest Partners, Partners Group, CDMO, Grays International, Acquisition, Pantheon, Growth, ESG, Fine chemical, Financial services, Tax advisor, Sterling

GHO Capital and Partners Group invest in Sterling Pharma Solutions, a leading pharmaceutical development and manufacturing organization

Key Points: 
  • GHO Capital and Partners Group invest in Sterling Pharma Solutions, a leading pharmaceutical development and manufacturing organization
    Since first partnering with GHO in 2019, Sterling Pharma Solutions has grown rapidly, tripling its revenues and quadrupling its earnings.
  • Sterling handles the development of complex APIs and subsequent scaling up of manufacturing from pre-clinical to commercial scale.
  • We are delighted to welcome Partners Group, which, alongside GHO, will support our ambitious global growth trajectory.
  • Sterling is a leading example of how our deep industry expertise, combined with the GHO growth playbook, can generate long-term, sustainable value.

GHO Capital and Partners Group invest in Sterling Pharma Solutions, a leading pharmaceutical development and manufacturing organization

Retrieved on: 
Thursday, May 25, 2023
LLP, Partnership, CG, GHO, ERM, Partner, API, AlpInvest Partners, Partners Group, CDMO, Grays International, Acquisition, Pantheon, Growth, ESG, Fine chemical, Financial services, Tax advisor, Sterling

GHO Capital and Partners Group invest in Sterling Pharma Solutions, a leading pharmaceutical development and manufacturing organization

Key Points: 
  • GHO Capital and Partners Group invest in Sterling Pharma Solutions, a leading pharmaceutical development and manufacturing organization
    Since first partnering with GHO in 2019, Sterling Pharma Solutions has grown rapidly, tripling its revenues and quadrupling its earnings.
  • Sterling handles the development of complex APIs and subsequent scaling up of manufacturing from pre-clinical to commercial scale.
  • We are delighted to welcome Partners Group, which, alongside GHO, will support our ambitious global growth trajectory.
  • Sterling is a leading example of how our deep industry expertise, combined with the GHO growth playbook, can generate long-term, sustainable value.

Validant Group Announces New Leadership

Retrieved on: 
Monday, May 15, 2023
Professional Services, Medical Supplies, Health, Medical Devices, Consulting, Pharmaceutical, Biotechnology, Validation (drug manufacture), IBM, Campbell Alliance, Medical Affairs Bureau, Partnership, Senior, GHO, IDEC, Health care, Multimedia, Development, Growth, Research, Syneos Health, FDA, Heidrick, OSAM, Heidrick & Struggles, Management, Audit, Pharmaceutical industry

View the full release here: https://www.businesswire.com/news/home/20230515005123/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20230515005123/en/
    Tim Dietlin, Chief Executive Officer (CEO), The Validant Group (Photo: Business Wire)
    “Tim brings a unique skill set to his role as CEO of the Validant Group.
  • Tim Dietlin brings more than 25 years of leadership experience to his role as CEO of the Validant Group.
  • “Together, the Validant Group will deliver a full-service platform that provides unmatched regulatory clarity at every phase of the product life cycle.
  • I look forward to cultivating and continuing to grow a united Validant Group that is stronger together and positioned for success.”
    The Validant Group is a global, full-service life science consulting company focused on managing and resolving complex regulatory issues.

Genesis Research Strengthens Board of Directors with Appointments of Professor Carole Longson MBE and Dr. S. Yin Ho, M.D.,M.B.A.

Retrieved on: 
Tuesday, January 17, 2023
Real-World Evidence, NICE, Knowledge, Research, University of Manchester, RWE, GHO, Software, Appointment, Software as a service, Doctor of Philosophy, Health technology assessment, Information technology, M.B.A, Management, Pharmaceutical industry

Genesis Research Strengthens Board of Directors with Appointments of Professor Carole Longson MBE and Dr. S. Yin Ho, M.D.,M.B.A.

Key Points: 
  • Genesis Research Strengthens Board of Directors with Appointments of Professor Carole Longson MBE and Dr. S. Yin Ho, M.D.,M.B.A.
  • HOBOKEN, NJ, 17 January 2023 - Genesis Research (“Genesis” or “the Company”), a leading provider of tech-enabled Real-World Evidence (RWE) and Health Economics and Outcomes Research (HEOR) services, has announced the appointment of Professor Carole Longson MBE and Dr. S. Yin Ho, M.D., M.B.A. to the Board of Directors.
  • Professor Carole Longson MBE is a renowned leader in health technology assessment with over 20 years of experience and considerable achievements in research, public and private sectors.
  • Additionally, Carole holds several Non-Executive Director and advisory roles and is an honorary Professor of Health Technology Assessment at Manchester University.

GHO Capital and The Vistria Group Complete Acquisition of Leading CDMO Alcami Corporation

Retrieved on: 
Tuesday, January 3, 2023
AUM, CGMP, Orientation, Microbiology, LLP, GHO, Madison Dearborn Partners, Growth, Multimedia, Acquisition, MDP, Learning, Datin, CDMO, Investment, Fine chemical, Financial services, Ampersand

WILMINGTON, N.C., Jan. 3, 2023 /PRNewswire/ -- Global Healthcare Opportunities, or GHO Capital Partners LLP ("GHO"), and The Vistria Group today announced that they have completed the acquisition of Alcami Corporation ("Alcami"), a leading pharmaceutical contract development and manufacturing organization (CDMO), from funds affiliated with Madison Dearborn Partners ("MDP") and Ampersand Capital Partners ("Ampersand").

Key Points: 
  • WILMINGTON, N.C., Jan. 3, 2023 /PRNewswire/ -- Global Healthcare Opportunities, or GHO Capital Partners LLP ("GHO"), and The Vistria Group today announced that they have completed the acquisition of Alcami Corporation ("Alcami"), a leading pharmaceutical contract development and manufacturing organization (CDMO), from funds affiliated with Madison Dearborn Partners ("MDP") and Ampersand Capital Partners ("Ampersand").
  • GHO Capital and The Vistria Group have acquired a 50/50 controlling interest in Alcami from funds affiliated with MDP and Ampersand.
  • Ampersand and Alcami Management have reinvested significant equity as part of the acquisition.
  • The Vistria Group is building a new kind of private investment firm that seeks to deliver both financial returns and societal impact.